3 Active Ingredients Maker, Branded Medicines Company and Formulations Producer Stocks With a Strong Future Roadmap: Neuland Laboratories, Eris Lifesciences and Lincoln Pharmaceuticals

Bulk drugs, branded medicines and formulations give investors a way to track businesses that sit close to everyday demand in India. Neuland Laboratories, Eris Lifesciences and Lincoln Pharmaceuticals cover an active ingredients maker, a branded medicines company and a formulations producer.

This list covers three bulk drugs, branded medicines and formulations with complete current figures: Neuland Laboratories, Eris Lifesciences and Lincoln Pharmaceuticals. Every figure comes from the latest reported financials and the 28 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Bulk Drugs, Branded Medicines and Formulations?

Bulk drugs, branded medicines and formulations are listed pharmaceutical companies that make active ingredients for global drug makers, sell branded medicines for heart, diabetes and long term conditions and produce tablets, capsules and injectables for domestic and export markets. Their earnings depend on launches, approvals and demand across markets.

Bulk Drugs, Branded Medicines and Formulations at a Glance

On valuation, Eris Lifesciences and Lincoln Pharmaceuticals trade at a P/E below the industry P/E, while Neuland Laboratories trades above it, which reflects the growth the market already expects. Readers comparing bulk drugs, branded medicines and formulations should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Bulk Drugs, Branded Medicines and Formulations Have a Strong Roadmap in India?

Bulk drugs, branded medicines and formulations have a strong roadmap in India because rising chronic illness, global sourcing of complex ingredients and higher healthcare spending keep widening the market for Indian pharmaceutical firms.

• Complex ingredients. Global drug makers source difficult molecules from India.
• Chronic care. Heart and diabetes medicines see steady repeat use.
• Export formulations. Approved plants open new markets.

Why Neuland Laboratories Features Among These Bulk Drugs, Branded Medicines and Formulations

Among the bulk drugs, branded medicines and formulations on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.

Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.

Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.

Why Eris Lifesciences Features Among These Bulk Drugs, Branded Medicines and Formulations

Among the bulk drug, branded medicine and generic formulation shares on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.

Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%.

In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.

Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.

Why Lincoln Pharmaceuticals Features Among These Bulk Drugs, Branded Medicines and Formulations

Among the three companies on this list, Lincoln Pharmaceuticals is an Ahmedabad-based maker of branded generics and formulations in India and exports to emerging markets, with products across anti-infectives, respiratory and pain care.

In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%.

Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0.

Roadmap: The company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.

What to watch: Track branded product growth, export orders and new launches.

Neuland Laboratories vs Eris Lifesciences vs Lincoln Pharmaceuticals on Key Financials

The table below sets the three bulk drugs, branded medicines and formulations side by side on revenue, profit and margin, using reported figures.

Neuland Laboratories posts the highest return on equity in this group at 19.4%. Eris Lifesciences combines the largest FY26 revenue at Rs 3,137 crore with the fastest revenue growth, a 22.9% compound annual rate. A useful habit with bulk drugs, branded medicines and formulations is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Bulk Drugs, Branded Medicines and Formulations

Every theme carries risks that deserve a check before any decision. For these bulk drugs, branded medicines and formulations, the main points are: Long-term bulk drug, branded medicine and generic formulation shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Pricing pressure. Generic prices can change by market.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter bulk drugs, branded medicines and formulations by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Bulk Drugs, Branded Medicines and Formulations

Bulk drugs, branded medicines and formulations work best when investors track growth, valuation and return on equity side by side. Neuland Laboratories, Eris Lifesciences and Lincoln Pharmaceuticals each have a clear plan to grow. Based on the 28 October 2026 close, Neuland Laboratories trades at Rs 19,970, Eris Lifesciences at Rs 1,175.4 and Lincoln Pharmaceuticals at Rs 558.1.

Download the Univest iOS App or Univest Android App to track bulk drugs, branded medicines and formulations, set price alerts and get research-backed stock ideas.

What are bulk drugs, branded medicines and formulations?

Ans. Bulk drugs, branded medicines and formulations are listed pharmaceutical companies that make active ingredients for global drug makers, sell branded medicines for heart, diabetes and long term conditions and produce tablets, capsules and injectables for domestic and export markets. Their earnings depend on launches, approvals and demand across markets. This list looks at three of them, Neuland Laboratories, Eris Lifesciences and Lincoln Pharmaceuticals, using reported FY22 to FY26 financials and the 28 October 2026 closing prices.

Which bulk drugs, branded medicines and formulations are covered in this list?

Ans. This list covers Neuland Laboratories, Eris Lifesciences and Lincoln Pharmaceuticals. Based on the 28 October 2026 close, Neuland Laboratories traded at Rs 19,970, Eris Lifesciences at Rs 1,175.4 and Lincoln Pharmaceuticals at Rs 558.1. Their return on equity ranges from 11.6% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 22.9%.

Why do bulk drugs, branded medicines and formulations have a strong future roadmap in India?

Ans. Bulk drugs, branded medicines and formulations have a strong roadmap in India because rising chronic illness, global sourcing of complex ingredients and higher healthcare spending keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Complex ingredients. Global drug makers source difficult molecules from India. Chronic care. Heart and diabetes medicines see steady repeat use. Export formulations. Approved plants open new markets. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Neuland Laboratories performed financially?

Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

How has Eris Lifesciences performed financially?

Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

How has Lincoln Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0. Looking ahead, the company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.

What risks should investors check before buying bulk drugs, branded medicines and formulations?

Ans. Investors should check a few risks before buying bulk drugs, branded medicines and formulations. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of bulk drugs, branded medicines and formulations investment advice?

Ans. No. This article is educational and uses publicly available data as of the 28 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.